Σύγκριση μεθόδων

	Δείκτης Ενεργότητας Νόσου του Crohn	Βαθμολογία Mayo για ελκώδη κολίτιδα
Πεδίο	Γαστρεντερολογία	Γαστρεντερολογία
Οικογένεια	Process / pipeline	Process / pipeline
Έτος προέλευσης	1976	1987
Δημιουργός	Best, W. R., Becktel, J. M., Singleton, J. W., and Kern, F.	Schroeder, K. W., Tremaine, W. J., and Ilstrup, D. M.
Τύπος	Clinician-rated	Clinician-rated
Θεμελιώδης πηγή	Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976). Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology, 70(3), 439–444.	Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987). Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. New England Journal of Medicine, 317(26), 1625–1629.
Εναλλακτικές ονομασίες	CDAI	Mayo Clinic Score, UC Mayo Score
Συναφείς	4	4
Σύνοψη	The Crohn's Disease Activity Index (CDAI) is a comprehensive, weighted index for assessing disease activity in Crohn's disease. Developed in 1976 by Best and colleagues for the National Cooperative Crohn's Disease Study, the CDAI integrates eight clinical and laboratory variables into a single score ranging from <150 (remission) to >450 (severe activity). Although more complex than symptom-based tools, the CDAI captures the multidimensional nature of Crohn's disease and remains the reference standard for severe disease assessment.	The Mayo Score is a validated tool for assessing disease activity in ulcerative colitis, integrating clinical symptoms and endoscopic findings. Introduced by Schroeder and colleagues in 1987, it has become the reference standard for UC activity assessment in clinical trials and practice. The score combines stool frequency, rectal bleeding, overall physician global assessment, and endoscopic subscore into a single 0–12 scale.